Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,616 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MDD Clear all
Completed Phase 4 Interventional

Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression

NCT00760097
View directory record Official record
Conditions
Depression
Interventions
Transcranial direct stimulation
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 2 Interventional Results available

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

NCT00985725
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Matching placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
33
States / cities
Imperial, California • Los Alamitos, California • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 1 Interventional Results available

Antidepressant Effects of NR2B in Major Depression

NCT00472576
View directory record Official record
Conditions
Major Depression
Interventions
MK-0657, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Results available

Memantine Augmentation of Antidepressants

NCT00344682
View directory record Official record
Conditions
Depressive Disorder
Interventions
memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Not applicable Interventional

A Treatment for Depression Via a Gamified Mobile Phone Application Based on a New Cognitive Model

NCT05685758
View directory record Official record
Conditions
Depression, Depressive Disorder, Clinical Depression, Major Depressive Disorder
Interventions
FTP-based therapeutic mobile-app
Other
Lead sponsor
Hedonia Ltd
Industry
Eligibility
20 Years to 50 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 28, 2026, 1:00 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

NCT04711915
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 28, 2026, 1:00 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Neutralizing Interleukin (IL)-6

NCT07493317
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tocilizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Not applicable Interventional

Depression Agency-Based Collaboration

NCT01566318
View directory record Official record
Conditions
Major Depression, Anxiety Disorder
Interventions
Problem-Solving Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery

NCT04481737
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Recurrent, Obesity, Cardiovascular Diseases, Diabetes, Smoking, Blood Pressure Disorders, Cholesterol, Elevated
Interventions
Peer-delivered and Technology Support Integrated Illness Management and Recovery, Peer support
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 28, 2026, 1:00 PM EDT
Terminated Phase 4 Interventional Results available

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

NCT00429169
View directory record Official record
Conditions
Depression
Interventions
Paroxetine, Bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Not applicable Interventional

Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder

NCT00179062
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
Interventions
olanzapine versus risperidone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Abilify Therapy for Reducing Comorbid Substance Abuse

NCT00208169
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
Interventions
Aripiprazole
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 24, 2007 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Not applicable Interventional Results available

CBT+ for Depression

NCT06001346
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ActiveCBT, CalmCBT
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

NCT02461927
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Ketamine + Naltrexone, Ketamine + Placebo, Placebo (psychoactive placebo midazolam) + Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 28, 2026, 1:00 PM EDT
Recruiting Phase 2 Interventional

Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

NCT06854224
View directory record Official record
Conditions
Suicide Risk, Major Depressive Disorder (MDD)
Interventions
Suvorexant (dual orexin receptor antagonist)
Drug
Lead sponsor
Marianne Goodman
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Not applicable Interventional

Individualized Non-invasive Brain Stimulation for the Treatment of Major Depressive Disorder

NCT06874374
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Interventions
Closed-loop tACS, Sham Comparator
Device
Lead sponsor
Pulvinar Neuro, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Not applicable Interventional

Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes

NCT03289923
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Sham TMS + Cognitive therapy, Active TMS + Cognitive therapy
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Not applicable Interventional

Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms

NCT00844974
View directory record Official record
Conditions
Major Depression, Bipolar Disorder
Interventions
Prevalence
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 28, 2026, 1:00 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccine as a Novel Experimental Model of the Behavioral Immune Response in Depression

NCT03756246
View directory record Official record
Conditions
Depression, Healthy
Interventions
Influenza Vaccine
Biological
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 28, 2026, 1:00 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

NCT07065240
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions
SPT-300, Placebo
Drug
Lead sponsor
Seaport Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Chino, California • Garden Grove, California • Glendale, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 3 Interventional

A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)

NCT00336713
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant (SR48968C), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 28, 2026, 1:00 PM EDT
Active, not recruiting Early Phase 1 Interventional

Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

NCT04846829
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, intermittent theta burst stimulation, intravenous citalopram hydrochloride (CIT), continuous theta burst stimulation
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Withdrawn Phase 4 Interventional

Creatine for Treatment of Depression Associated With Type 2 Diabetes

NCT03202095
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine Monohydrate
Drug
Lead sponsor
University of Utah
Other
Eligibility
20 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Not applicable Interventional

A Study of the Cost Effectiveness of Generalist Care Managers for Depression Treatment in Medicaid Recipients

NCT00373477
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Generalist Care Manager vs Usual Care
Procedure
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Asheville, North Carolina • Marshall, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2006 · Synced Oct 28, 2026, 1:00 PM EDT